Akademik Veri Yönetim Sistemi
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, sa.12, ss.1120-1124, 2023 (ESCI)
Aim: Surfactant production by type II pneumocytes starts at 24-25 weeks of gestation and reaches optimum level at 36-37 weeks. The aim of this study was to retrospectively evaluate the efficacy of three different surfactant preparations on the respiratory functions of preterm infants. Material and Methods: This study was carried out retrospectively in newborns with respiratory distress syndrome who received inpatient treatment and used surfactant in the Neonatal Intensive Care Unit of Selcuk University Faculty of Medicine, Department of Pediatrics, in 2017-2021. The study group included 111 preterm infants diagnosed with RDS, with a delivery week of 32 and below, who were administered one of three different animal-derived surfactant preparations (poractant alfa, calfactant and beractant). Results: In this study, poractant alfa was applied to 48.65% (n=54) of the patients, calfactant to 13.51% (n=15), and beractant to 37.84% (n=42) of the patients due to RDS. There was no statistically significant difference between the three different surfactant groups in terms of maternal drug use, antenatal steroid use, which affect the development of RDS in newborns. Gender, type of birth, gestational age, maternal age, 1-min Apgar scores, and 1-, 3-, 5-, and 7-day FiO(2) levels did not differ between the three groups. Discussion: The efficacy of poractant alfa, beractant and calfactant used in newborns with RDS is similar.